Indegene Ltd IPO

Indegene Limited provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. The Company combines over two decades of healthcare domain expertise and its technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 31, 2023, the company had 65 active clients whom it caters to from six operation hubs and 17 offices located across North America, Europe and Asia.

Open Demat Account

50years

Indegene Ltd IPO Details

Details

Total Shares OfferedOffer to PublicRetail Max (Shares)Pre Issue Promoters HoldingExchangeIssue size
₹ 407.47 L₹ 239.33 L₹ 141.65 LTBABSE₹ 1841.76 Cr
IPO Open DateClose DateLot SizeMin InvestmentIssue TypeListing Date
06 May, 2408 May, 2433 ₹ 14,190 Book Building13 May, 24

Indegene Ltd IPO Dates

  • 06 May 2024

    Opening date

  • 08 May 2024

    Closing date

  • 09 May 2024

    Basis of
    Allotment

  • 10 May 2024

    Initiation of
    Refunds

  • 10 May 2024

    Credit of
    Shares

  • 13 May 2024

    Listing date

Details

SectorType
SectorMiscellaneous
Sub SectorNA
Issue TypeBook Building

Subscription Status

*Values are in Lakhs

Investor TypeSubscription TimesShares Offered*Shares Bid*
QIB77.09x202351711559865945
NII56.22x6070551341307846
Retail8.12x14164620114979788
Employee7.32x2765492024583
Total49.53x407468912018178162

Subscription Status

Investor Type

QIB

NII

Retail

Employee

Total

*Values are in Lakhs

Indegene Ltd Financial Status

Income Statement

Balance Sheet

Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations211.70208.30193.50
EBITDA242.80240.00217.10
PAT137.90130.20132.70
Total Assets530.30549.10427.20
Share Capital44.4044.300.40
Total Borrowings136.7094.3038.90
Operating Activities (Net Cash)169.00161.90156.30
Investing Activities (Net Cash)623.80400.30203.30
Financing Activities (Net Cash)136.7094.3038.90
Net Cashflow15.6054.0038.80

Particulars (in Rs. Crores)

Revenue from operations

EBITDA

PAT

Total Assets

Share Capital

Total Borrowings

Operating Activities (Net Cash)

Investing Activities (Net Cash)

Financing Activities (Net Cash)

Net Cashflow

About Indegene Ltd

Indegene Limited was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of the Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by its Shareholders at the EGM held on February 29, 2016 the name of the Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of the Company was changed to better reflect the nature of business undertaken by the Company. Thereafter, the registered office of the Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, the Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by its Shareholders at the EGM held on November 7, 2022 and the name of the Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to the Company by the RoC, on November 17, 2022.

The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at Rs.138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or Rs.95.4 trillion (US$ 1.2 trillion) of such sales. Combined sales of biopharmaceutical companies and medical devices companies are estimated to reach Rs.163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at Rs.12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach Rs.15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales.

Indegene Limited provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. The Company combines over two decades of healthcare domain expertise and its technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 31, 2023, the company had 65 active clients whom it caters to from six operation hubs and 17 offices located across North America, Europe and Asia.

Peer Comparison:

  • No Listed Industry Peers

Indegene Ltd IPO Key Points

Strengths

  • Domain expertise in healthcare.
  • Robust digital capabilities and in-house developed technology portfolio.
  • Track record of establishing long-standing client relationships.
  • Global delivery model.
  • Experienced management and motivated talent pool supported by marquee investors.

Risk

  • Its business is solely focused on the life sciences industry and may be adversely impacted by factors affecting the life sciences industry, including the growth of the overall life sciences industry, outsourcing and other trends.
  • As its business is solely focused on the life sciences industry and a significant portion of its business is attributable to certain large clients located in North America and Europe, its business and profitability is dependent on factors affecting the life sciences industry and the company continuing relationships with such key clients.
  • Its business and revenue models may be unfamiliar to prospective investors.

Strategy

  • Strengthen its go to market engine.
  • Develop its technology portfolio.
  • Pursue strategic acquisitions.
  • Focus on operational excellence.
  • Domain expertise in healthcare.
  • Robust digital capabilities and in-house developed technology portfolio.
  • Track record of establishing long-standing client relationships.
  • Global delivery model.
  • Experienced management and motivated talent pool supported by marquee investors.

How To Apply for Indegene Ltd IPO Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

Get your FAQs right

Indegene Ltd's IPO offers shares for up to ₹ 0.01 L It begins on May 6, 2024 and ends on May 8, 2024.

The price of Indegene Ltd IPO ranges between ₹430 to ₹452 per share.

The Indegene Ltd IPO opens on May 6, 2024 and closes on May 8, 2024.

The allotment for the Indegene Ltd IPO will be finalised on May 9, 2024. The shares will be listed on BSE and NSE on May 13, 2024.

The minimum lot size for Indegene Ltd IPO is 33 shares, priced between ₹430 to ₹452 per share.

The GMP (Grey Market Premium) of Indegene Ltd IPO fluctuates based on market demand and sentiment.

To check the allotment status of Indegene Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

The Indegene Ltd IPO is getting listed on the BSE and NSE. Bidding opens on May 6, 2024, and closes on May 8, 2024. The allotment is finalised on May 9, 2024.

To apply for the Indegene Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.